Compare the peptide evidence

Semaglutide, thymosin alpha-1, BPC-157, and MOTS-c all attract health-related questions, but their research records differ substantially. Some studies administer a treatment to people and compare outcomes. Others investigate animal tissues, cells, or a naturally occurring blood measurement. The distinction changes what a finding can support.

The table is a comparison of questions, not a ranking of treatments. A favorable mechanism cannot be assigned the same meaning as a clinical outcome, and a study’s size alone does not make it answer a different question.

The SELECT trial of semaglutide found fewer major cardiovascular events in people with established cardiovascular disease and overweight or obesity, without diabetes. That is evidence about a defined treatment, outcome, and population. It does not automatically apply to every person interested in cardiovascular health.

The TESTS trial of thymosin alpha-1 found no significant reduction in 28-day mortality among adults with sepsis. A well-conducted trial can provide important information even when the result is not positive. This outcome sets a limit on a specific claim; it does not make all immune mechanisms irrelevant or establish a different benefit.

The BPC-157 vessel-growth experiments included chick membrane models, rats, and cultured human vascular cells. They help describe an experimental repair pathway. They do not establish better healing in people. The presence of human cells does not turn laboratory work into a clinical treatment trial.

The MOTS-c hemodialysis study involved people, but it measured the peptide they already made. It did not administer MOTS-c. A biomarker, a measurement associated with a condition or outcome, can be useful without being a treatment target. Changing a marker does not necessarily change the outcome with which it is associated.

Older work can explain where a hypothesis came from. A review can bring many studies together. A newer trial can then test a narrower question more rigorously. Reading these kinds of publications together makes a more reliable comparison than treating every paper as another vote for a benefit.

For example, the thymosin alpha-1 review published in 2020 provides historical and clinical context, while TESTS reports a later controlled sepsis result. The dates matter because the earlier review could not include a later trial. The same principle applies when a broad review discusses experimental promise but a specific treatment question remains unanswered.

Semaglutide has FDA-approved medicines. Thymosin alpha-1 has a history of use abroad as thymalfasin but no FDA marketing approval in the United States. BPC-157 and MOTS-c have no FDA-approved medicines. These regulatory differences belong alongside the study differences rather than being treated as a substitute for them.

On the FDA page current as of April 22, 2026, BPC-157, MOTS-c, and thymosin alpha-1 are listed as nominated but withdrawn. Withdrawal does not establish clearance or permission to compound. Compounded medicines are not FDA-approved. A shared ingredient name also cannot verify that a preparation matches the one used in a published study.

A larger evidence base can describe harms more clearly; a smaller one may leave them largely unknown. Semaglutide’s safety review describes gastrointestinal effects and other clinical cautions. BPC-157’s research review highlights the limits of sparse human data. An absence of reported problems in a tiny study cannot establish lower risk.

Each compound page gives its own safety context. A useful clinical conversation asks which evidence applies to the health problem, what benefit is being considered, and what uncertainty remains. This comparison supplies reading context rather than a personal treatment choice.